The Pathogenesis and Prognostic Factors of Lymphoma

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT06203652
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Real-world regimen — OTHER
    The final personalized management strategy is determined based on current conventional treatment options, physician and patient preferences.The following protocols: chemotherapy, immunochemotherapy,Anti-cd20 monoclonal antibody, BTKi and so on

Study Details

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Key Dates

First listed
Jan 12, 2024
Start date
Jun 5, 2023
Status verified
Jan 2024
Primary completion
Dec 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
2,000 participants (estimated)

Arms

  • Arm: All enrolled patients
    All patients who are eligible for participation to the study.

Primary Outcome Measure

OS [ Time Frame: Baseline up to data cut-off (Up to approximately 20 years) ]

Central Contacts

Related Studies